Pirfenidone regulates pericellular proteolysis in cancer

dc.contributor.advisorWygrecka, Malgorzata
dc.contributor.advisorFugmann, Tim
dc.contributor.authorKrämer, Matthias
dc.date.accessioned2022-09-12T09:34:43Z
dc.date.available2022-09-12T09:34:43Z
dc.date.issued2022
dc.description.abstractThe orally available drug pirfenidone, which is approved for the therapy of idiopathic pulmonary fibrosis is inhibiting the proliferation and migration of lung cancer cells. This effects are partially mediated vie the regulation of the activity of the proteolytic system, especially via PAI-1.de_DE
dc.identifier.urihttps://jlupub.ub.uni-giessen.de//handle/jlupub/6479
dc.identifier.urihttp://dx.doi.org/10.22029/jlupub-5930
dc.language.isoende_DE
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectPirfenidonede_DE
dc.subjectlung cancerde_DE
dc.subject.ddcddc:610de_DE
dc.titlePirfenidone regulates pericellular proteolysis in cancerde_DE
dc.typedoctoralThesisde_DE
dcterms.dateAccepted2022-03-22
local.affiliationFB 11 - Medizinde_DE
thesis.levelthesis.doctoralde_DE

Dateien

Originalbündel
Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
KraemerMatthias-2022-03-22.pdf
Größe:
3.51 MB
Format:
Adobe Portable Document Format
Beschreibung:
Lizenzbündel
Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
7.58 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: